CDMO Cambrex Scooped up for $2.4 Billion, an Industrial Info Market Brief

---

Contract development and manufacturing organization (CDMO) Cambrex is being purchased by private-equity firm Permira Funds. The $2.4 billion transaction, expected to close during fourth-quarter 2019, is just another deal in the Pharma-Bio Industry's ongoing merger & acquisition spree.

Cambrex is in the midst of a $15 million upgrade in High Point, North Carolina, including its current 35,000-square-foot facility (4180 Mendenhall Oaks Parkway) and another 40,000-square-foot building (4170 Mendenhall Oaks Parkway), which is currently occupied by vTv Therapeutics, to increase contract production capacity of small molecule Active Pharmaceutical Ingredients (APIs) and intermediates.